Clinical Trial

Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multicenter, open-label study of Intratumoral Vusolimogene Oderparepvec (VO) to investigate safety and estimate when used in combination with pembrolizumab for treating participants with angiosarcoma. This is the first study evaluating this novel combination in participants with advanced angiosarcoma who have progressed after prior immunotherapy.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-09
Trial Details
NCT Number NCT06898970
Lead Sponsor Varun Monga, MBBS
Collaborators: Replimune, Inc.
Conditions Angiosarcoma, Angiosarcoma, Adult
Enrollment 18 participants
Start Date 2026-01-09
Primary Completion 2029-10-31 (estimated)
Study Completion 2029-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-08